VEGFA Polyclonal Antibody, Cy3 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-20393R-Cy3-100uL |
| Product Name | VEGFA Polyclonal Antibody, Cy3 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Rat |
| Predicted Reactivity | Dog |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VEGFA |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 7422 |
| Swiss Prot | P15692 |
| Subcellular location | Secreted |
| Synonyms | Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; Vegf; VEGFA; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF; VEGF A Precursor. |
| Background | This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is VEGFA Polyclonal Antibody, Cy3 Conjugated (bs-20393R-Cy3) validated for, and at what dilution?
bs-20393R-Cy3 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does VEGFA Polyclonal Antibody, Cy3 Conjugated (bs-20393R-Cy3) react with?
Tested reactivity: Human, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Dog.
How should bs-20393R-Cy3 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise VEGFA Polyclonal Antibody, Cy3 Conjugated (bs-20393R-Cy3)?
KLH conjugated synthetic peptide derived from human VEGFA
What are the excitation and emission wavelengths of the Cy3 conjugate (bs-20393R-Cy3)?
Cy3 on bs-20393R-Cy3: excitation / emission 512,550nm/570,615nm.